<SEC-DOCUMENT>0001213900-21-000903.txt : 20210107
<SEC-HEADER>0001213900-21-000903.hdr.sgml : 20210107
<ACCEPTANCE-DATETIME>20210107163138
ACCESSION NUMBER:		0001213900-21-000903
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210107
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210107
DATE AS OF CHANGE:		20210107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			American BriVision (Holding) Corp
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-91436
		FILM NUMBER:		21514568

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ecology Coatings, Inc.
		DATE OF NAME CHANGE:	20070711
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea132646-8k_americanbrivi.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
January 7, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AMERICAN BRIVISION (HOLDING) CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>333-91436</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>26-0014658</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer<BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 49%; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>44370 Old Warm Springs Blvd.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fremont, CA </B></P></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>94538</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number including
area code: <B>(510) 668-0881</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:
None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect; 230.405 of this chapter)
or Rule 12b&ndash;2 of the Securities Exchange Act of 1934 (&sect; 240.12b&ndash;2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 7 &ndash; Regulation FD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01 Regulation FD Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8.01 Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 5, 2021, American BriVision (Holding)
Corporation (the &ldquo;<B>Company</B>&rdquo;, or &ldquo;<B>we</B>&rdquo;) issued a letter to its shareholders disclosing a summary
of events from fiscal year 2020 and goals for fiscal 2021 (the &ldquo;Shareholder Letter&rdquo;). The Shareholder Letter was sent
out via the Company's email distribution list and posted to the Company's website. The Company also issued a press release including
the Shareholder Letter on January 6, 2021. A copy of the&nbsp;Shareholder Letter and the press release is filed as Exhibit 99.1
and Exhibit 99.2, respectively to this Current Report on Form 8-K and each is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statement and Exhibits </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 91%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea132646ex99-1_american.htm"><FONT STYLE="font-size: 10pt">L</FONT>etter to Shareholders dated January 5, 2021</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>99.2</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea132646ex99-2_american.htm">Press Release</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>American BriVision (Holding) Corporation</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">January 7, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Andy An</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Andy An</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>











</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea132646ex99-1_american.htm
<DESCRIPTION>LETTER TO SHAREHOLDERS DATED JANUARY 5, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="text-align: left; width: 50%; vertical-align: bottom"><P STYLE="margin-right: 0; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>
                           <P STYLE="margin-right: 0; margin-top: 0; margin-bottom: 0">http://abvcpharma.com/</P></TD>
    <TD STYLE="text-align: right; width: 50%; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">44370 Old Warm Springs Blvd.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fremont, CA 94538</P></TD></TR>
</TABLE>
<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Shareholder:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Now that 2020 has ended, we believe it will be informative to
you, our shareholders, to hear about our goals for 2021. But first, we note that 2020 was an exceptional year for the company,
particularly with respect to our medical device, Vitargus&reg;, and our medicine ABV-1505, which is designed to alleviate attention-deficit
hyperactivity disorder (ADHD).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#38568;&#33879;2020&#24180;&#21363;&#23559;&#32080;&#26463;&#65292;&#25105;&#20497;&#30456;&#20449;&#24744;&#65292;&#20063;&#26159;&#25105;&#20497;&#30340;&#32929;&#26481;&#20043;&#19968;&#65292;&#26371;&#24819;&#35201;&#20102;&#35299;&#20844;&#21496;&#26410;&#20358;&#30340;&#39000;&#26223;&#21450;&#30446;&#27161;&#12290;&#20294;&#26159;&#39318;&#20808;&#65292;&#25105;&#20497;&#24819;&#35498;&#30340;&#26159;2020&#24180;&#23565;&#20844;&#21496;&#20358;&#35498;&#26159;&#38750;&#24120;&#29305;&#21029;&#30340;&#19968;&#24180;&#65292;&#23588;&#20854;&#26159;&#23565;&#26044;&#25105;&#20497;&#30340;&#21109;&#26032;&#37291;&#30274;&#22120;&#26448;Vitargus&reg;&#65292;&#20197;&#21450;&#25105;&#20497;&#27491;&#22312;&#38283;&#30332;&#20013;&#33021;&#22816;&#28187;&#36629;&#27880;&#24847;&#21147;&#19981;&#38598;&#20013;&#21450;&#36942;&#21205;&#30151;&#65288;ADHD&#65289;&#30340;&#26893;&#29289;&#26032;&#34277;ABV-1505&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B><U>2020 - A Year of Accomplishment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>Vitargus&reg;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Vitargus&reg; is the world&rsquo;s first bio-degradable
vitreous substitute utilized during vitrectomy surgery. Vitargus&reg; offers important advantages over current vitreous substitutes
by minimizing medical complications and reducing the need for additional surgeries. In October of 2020, we sent a full clinical
study report (CSR) of Vitargus&reg; First-in-Human Phase I Clinical Trial to the United States Food and Drug Administration. The
participants in the study showed significant improvement in visual acuity immediately following retina re-attachment surgery. Additionally,
since Vitargus&reg; is a stable semisolid gel adhering to the retina during surgery, patients do not need to remain face-down after
surgery, which provides a significant improvement to patients&rsquo; post-surgical comfort. Vitargus&reg; addresses a large and
growing market according to Grand View Research, with worldwide vitrectomy cases expected to increase from 1.26 million in 2012
to 4 million by 2030 (6.8% CAGR), reaching a $2 billion market value.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Vitargus&reg;&#26159;&#19990;&#30028;&#19978;&#31532;&#19968;&#20491;&#22312;&#29627;&#29827;&#39636;&#21106;&#38626;&#25163;&#34899;&#24460;&#65292;&#21487;&#20351;&#29992;&#30340;&#29627;&#29827;&#39636;&#26367;&#20195;&#29289;&#65292;&#23427;&#26159;&#19968;&#20491;&#33021;&#22816;&#34987;&#33258;&#39636;&#21560;&#25910;&#38477;&#35299;&#30340;&#26367;&#20195;&#29289;&#12290;&#33287;&#30446;&#21069;&#30340;&#29627;&#29827;&#39636;&#26367;&#20195;&#29289;&#30456;&#27604;&#65292;Vitargus&reg;&#19981;&#20294;&#33021;&#28187;&#23569;&#25163;&#34899;&#24460;&#20341;&#30332;&#30151;&#20006;&#19988;&#21487;&#20197;&#20813;&#21435;&#20108;&#27425;&#25110;&#22810;&#27425;&#25163;&#34899;&#30340;&#38656;&#27714;&#12290;&#22240;&#27492;&#65292;&#25105;&#20497;&#30456;&#20449;&#29986;&#21697;&#19978;&#24066;&#24460;&#24517;&#23450;&#26371;&#23565;&#24066;&#22580;&#36896;&#25104;&#37325;&#22823;&#24433;&#38911;&#12290;
2020&#24180;10&#26376;&#65292;&#25105;&#20497;&#21521;&#32654;&#22283;&#39135;&#21697;&#21644;&#34277;&#29289;&#31649;&#29702;&#23616;(FDA)&#30332;&#36865;&#20102;Vitargus&reg;&#20154;&#39636;&#39318;&#27425;&#33256;&#24202;&#35430;&#39511;&#30340;&#23436;&#25972;&#33256;&#24202;&#30740;&#31350;&#22577;&#21578;&#65288;CSR&#65289;&#65292;&#20854;&#20013;&#25152;&#26377;&#21463;&#35430;&#32773;&#22312;&#35222;&#32178;&#33180;&#21085;&#38626;&#40655;&#21512;&#25163;&#34899;&#24460;&#65292;&#35222;&#21147;&#39340;&#19978;&#29554;&#24471;&#20102;&#26126;&#39023;&#25913;&#21892;&#12290;&#27492;&#22806;&#65292;&#30001;&#26044;Vitargus&reg;&#26159;&#22312;&#25163;&#34899;&#20013;&#29992;&#26044;&#40655;&#22238;&#35222;&#32178;&#33180;&#30340;&#19968;&#20491;&#20855;&#26377;&#31337;&#23450;&#24615;&#30340;&#39006;&#22266;&#39636;&#20957;&#33184;&#65292;&#22240;&#27492;&#24739;&#32773;&#22312;&#25163;&#34899;&#24460;&#28961;&#38656;&#20445;&#25345;&#33225;&#37096;&#26397;&#19979;&#65292;&#23565;&#26044;&#24739;&#32773;&#30340;&#34899;&#24460;&#29983;&#27963;&#26377;&#39023;&#33879;&#30340;&#25913;&#21892;&#12290;&#26681;&#25818;Grand
View Research&#30340;&#30740;&#31350;&#22577;&#21578;&#65292;Vitargus&reg;&#30340;&#26410;&#20358;&#24066;&#22580;&#40848;&#22823;&#19988;&#19981;&#26039;&#25104;&#38263;&#65292;&#20840;&#29699;&#29627;&#29827;&#39636;&#20999;&#38500;&#25163;&#34899;&#30149;&#20363;&#38928;&#35336;&#23559;&#24478;2012&#24180;&#30340;126&#33836;&#20363;&#22686;&#21152;&#21040;2030&#24180;&#30340;400&#33836;&#20363;&#65288;&#35079;&#21512;&#24180;&#22686;&#38263;&#29575;&#28858;6.8&#65285;&#65289;&#65292;&#24066;&#22580;&#20729;&#20540;&#20272;&#36948;&#21040;20&#20740;&#32654;&#20803;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B></B></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-right: 0; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt 0 0pt 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-right: 0; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt 0 0pt 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>ABV-1505 - ADHD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Equally as exciting, a successful Phase II, Part 1 Clinical
Trial of ABV 1505 was completed at the University of California, San Francisco (UCSF) Medical Center and a clinical study report
(CSR) was issued this past November. ABV-1505 targets adult attention deficit disorder and has the same active pharmaceutical ingredient,
PDC-1421, used in ABV-1504, one of our drugs that successfully completed a Phase II clinical study conducted at Stanford University
to treat major depression disorder (MDD) in 2019.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">In July of 2020, we filed for a patent for certain aspects
of ABV-1504 in the United States under the <FONT STYLE="background-color: #FAFAFA">Patent Cooperation Treaty (PCT); this treaty
has legal effect in other countries. We believe that the patent, when granted, will greatly enh</FONT>ance our existing portfolio
of PDC-1421 related patents and strengthen our global IP position. PDC-1421, the active ingredient in ABV-1504 and ABV-1505, is
an extract of <I>Polygala tenuifolia,</I> a plant grown primarily in China.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>ABV-1505 - &#27880;&#24847;&#21147;&#19981;&#38598;&#20013;&#21450;&#36942;&#21205;&#30151;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#21516;&#27171;&#20196;&#20154;&#25391;&#22894;&#30340;&#26159;&#65292;&#22312;&#32654;&#22283;&#21152;&#24030;&#22823;&#23416;&#33290;&#37329;&#23665;&#20998;&#26657;&#65288;UCSF&#65289;&#37291;&#23416;&#20013;&#24515;&#25104;&#21151;&#22320;&#23436;&#25104;&#20102;ABV
1505&#30340;&#33256;&#24202;II&#26399;&#31532;&#19968;&#37096;&#20998;&#35430;&#39511;&#65292;&#20006;&#26044;2020&#24180;11&#26376;&#30332;&#24067;&#20102;&#33256;&#24202;&#30740;&#31350;&#22577;&#21578;&#65288;CSR&#65289;&#12290;
ABV-1505&#37341;&#23565;&#25104;&#20154;&#27880;&#24847;&#21147;&#19981;&#38598;&#20013;&#30340;&#32570;&#38519;&#65292;&#25505;&#29992;&#20102;&#33287;ABV-1504&#20013;&#26377;&#30456;&#21516;&#27963;&#24615;&#30340;&#34277;&#29289;&#25104;&#20998;PDC-1421&#20358;&#27835;&#30274;&#27880;&#24847;&#21147;&#19981;&#38598;&#20013;&#30149;&#20154;&#12290;ABV-1504&#26159;&#25105;&#20497;&#22312;2019&#24180;&#30001;&#32654;&#22283;&#26031;&#22374;&#31119;&#22823;&#23416;&#25104;&#21151;&#23436;&#25104;&#29992;&#26044;&#27835;&#30274;&#37325;&#24230;&#25233;&#39729;&#30151;&#65288;MDD&#65289;&#30340;II&#26399;&#33256;&#24202;&#30740;&#31350;&#30340;&#34277;&#29289;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">2020&#24180;7&#26376;&#65292;&#25105;&#20497;&#26681;&#25818;&#12298;&#23560;&#21033;&#21512;&#20316;&#26781;&#32004;&#12299;&#65288;PCT&#65289;&#22312;&#32654;&#22283;&#30003;&#35531;&#20102;ABV-1504&#22312;&#27835;&#30274;&#37325;&#24230;&#25233;&#39729;&#30151;&#26041;&#38754;&#30340;&#23560;&#21033;&#65307;
&#12298;&#23560;&#21033;&#21512;&#20316;&#26781;&#32004;&#12299;&#22312;&#20854;&#20182;&#22283;&#23478;&#20063;&#20855;&#26377;&#30456;&#21516;&#30340;&#27861;&#24459;&#25928;&#21147;&#12290;
&#25105;&#20497;&#30456;&#20449;&#65292;&#35442;&#23560;&#21033;&#19968;&#32147;&#26680;&#20934;&#65292;&#23559;&#20351;&#25105;&#20497;&#29694;&#26377;PDC-1421&#30456;&#38364;&#30340;&#23560;&#21033;&#32068;&#21512;&#26356;&#21152;&#23436;&#25972;&#35920;&#23500;&#65292;&#21487;&#20197;&#25345;&#32396;&#24375;&#21270;&#25105;&#20497;&#22312;&#20840;&#29699;&#30693;&#35672;&#29986;&#27402;&#30340;&#38936;&#20808;&#22320;&#20301;&#12290;
PDC-1421&#26159;&#36960;&#24535;&#30340;&#33795;&#21462;&#29289;&#65292;&#32780;&#36960;&#24535;&#26159;&#19968;&#31278;&#20027;&#35201;&#22312;&#20013;&#22283;&#29983;&#38263;&#30340;&#26893;&#29289;&#65292;&#33258;&#21476;&#20197;&#20358;&#38263;&#26399;&#20351;&#29992;&#26044;&#20013;&#37291;&#23416;&#65292;&#20855;&#26377;&#23433;&#23527;&#23450;&#31070;&#20043;&#25928;&#29992;&#65292;&#25105;&#20497;&#29992;PDC-1421&#20316;&#28858;ABV-1504
&#21450;ABV-1505&#30340;&#20027;&#35201;&#25104;&#20998;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>ABV-2002 &ndash; Corneal Storage Solution</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">On November 4, 2020, we executed an amendment to our development
collaboration agreement with BioFirst, an affiliate, to add a Corneal Storage Solution and an Intraocular Irrigation Solution to
the agreement. The Corneal Storage Solution is utilized during a corneal transplant procedure to replace a damaged or diseased
cornea. The Intraocular Irrigation Solution has broader utilization and is used during a variety of ocular procedures.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Initially, ABVC will focus on the Corneal Storage Solution,
designated ABV-2002 under ABVC&rsquo;s product identification system. A donor cornea is stored in the ABV-2002 solution prior to
penetrating keratoplasty (full thickness cornea transplant) or endothelial keratoplasty (back layer cornea transplant). Early testing
indicates that ABV-2002 may be more effective at protecting the cornea during long-term storage than other storage media currently
available and can be manufactured at lower cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo --><B>2</B><!-- Field: /Sequence --> of <B>7</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>ABV-2002 &ndash; &#35282;&#33180;&#20445;&#23384;&#28082;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">2020&#24180;11&#26376;4&#26085;&#65292;&#25105;&#20497;&#33287;&#30456;&#38364;&#20844;&#21496;&#65292;&#21488;&#28771;&#28377;&#29305;&#29983;&#29289;&#31185;&#25216;&#32929;&#20221;&#26377;&#38480;&#20844;&#21496;&#65292;&#31805;&#32626;&#20102;&#19968;&#38917;&#20849;&#21516;&#38283;&#30332;&#21512;&#32004;&#30340;&#20462;&#27491;&#26696;&#65292;&#22312;&#21332;&#35696;&#20013;&#22686;&#21152;&#20102;&#35282;&#33180;&#20445;&#23384;&#28082;&#37197;&#26041;&#21644;&#30524;&#31185;&#25163;&#34899;&#27798;&#27927;&#28082;&#30340;&#29986;&#21697;&#25480;&#27402;&#12290;&#35282;&#33180;&#20445;&#23384;&#28082;&#21487;&#20197;&#23384;&#25918;&#24478;&#27491;&#24120;&#20154;&#31227;&#26893;&#20358;&#30340;&#35282;&#33180;&#65292;&#21487;&#29992;&#26044;&#21462;&#20195;&#21463;&#25613;&#25110;&#24739;&#30149;&#30340;&#35282;&#33180;&#12290;&#30524;&#31185;&#25163;&#34899;&#27798;&#27927;&#28082;&#21063;&#20855;&#26377;&#26356;&#24291;&#27867;&#30340;&#29992;&#36884;&#65292;&#21487;&#29992;&#26044;&#19981;&#21516;&#38917;&#30446;&#30340;&#30524;&#31185;&#25163;&#34899;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#25105;&#20497;&#21021;&#27493;&#30340;&#35215;&#21123;&#26159;&#65292;ABVC&#20808;&#23560;&#27880;&#26044;&#35282;&#33180;&#20445;&#23384;&#28082;&#65292;&#20844;&#21496;&#29986;&#21697;&#20195;&#30908;&#28858;ABV-2002&#65292;&#30340;&#37197;&#26041;&#21644;&#29986;&#21697;&#25480;&#27402;&#12290;&#25424;&#36104;&#32773;&#30340;&#35282;&#33180;&#21487;&#20197;&#20786;&#23384;&#22312;ABV-2002
&#28342;&#28082;&#20013;&#65292;&#20043;&#24460;&#20877;&#25033;&#29992;&#26044;&#31359;&#36879;&#24615;&#35282;&#33180;&#31227;&#26893;&#34899;&#65288;&#20840;&#23652;&#30340;&#35282;&#33180;&#31227;&#26893;&#65289;&#25110;&#20839;&#30382;&#35282;&#33180;&#31227;&#26893;&#34899;&#65288;&#24460;&#23652;&#35282;&#33180;&#31227;&#26893;&#65289;&#12290;
&#25105;&#20497;&#21021;&#26399;&#28204;&#35430;&#30340;&#32080;&#26524;&#39023;&#31034;&#65292;&#22312;&#38263;&#26399;&#30340;&#20786;&#23384;&#36942;&#31243;&#20013;ABV-2002&#21487;&#33021;&#27604;&#30446;&#21069;&#20854;&#20182;&#30340;&#20445;&#23384;&#28082;&#26356;&#33021;&#26377;&#25928;&#22320;&#20445;&#35703;&#35282;&#33180;&#65292;&#20006;&#19988;&#35069;&#36896;&#25104;&#26412;&#20063;&#21487;&#20197;&#27604;&#20854;&#20182;&#20154;&#20302;&#30340;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>Financial</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Finally, 2020 was a year that set the stage for a potential
listing on NASDAQ, an elusive goal we have been pursuing for over a year. To reach this goal and fund our clinical trials, we improved
our balance sheet during the year by raising more than $8.0 million of fresh equity and converting more than $4.0 million of debt
to equity. We are pleased that both new and previous investors stepped up to assure that we have the resources to continue the
execution of our business plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">In addition, on December 28, 2020
an S-1 registration statement to register more than 4 million shares already owned by our shareholders was declared effective by
the US Securities &amp; Exchange Commission. This will increase the number of shares in our outstanding share float which we believe
will result in an increase in the liquidity of our stock trading.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&#36001;&#21209;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#26368;&#24460;&#65292;2020&#24180;&#26159;&#35731;&#25105;&#20497;&#26377;&#27231;&#26371;&#22312;NASDAQ&#19978;&#24066;&#22880;&#23450;&#22522;&#30990;&#30340;&#19968;&#24180;&#65292;&#36889;&#20063;&#26159;&#25105;&#20497;&#19968;&#24180;&#22810;&#20358;&#19981;&#26039;&#21162;&#21147;&#65292;&#19968;&#30452;&#36861;&#27714;&#30340;&#30446;&#27161;&#12290;
&#28858;&#20102;&#36948;&#21040;&#36889;&#19968;&#30446;&#27161;&#20006;&#28858;&#25105;&#20497;&#30340;&#33256;&#24202;&#35430;&#39511;&#25214;&#21040;&#36275;&#22816;&#30340;&#36039;&#37329;&#65292;&#36889;&#19968;&#24180;&#20013;&#25105;&#20497;&#25913;&#21892;&#20102;&#20844;&#21496;&#30340;&#36039;&#29986;&#36000;&#20661;&#34920;&#65292;&#21215;&#38598;&#20102;&#36229;&#36942;800&#33836;&#32654;&#20803;&#30340;&#26032;&#32929;&#26412;&#65292;&#20006;&#23559;&#21407;&#26412;&#36229;&#36942;400&#33836;&#32654;&#20803;&#30340;&#20661;&#21209;&#36681;&#25563;&#28858;&#32929;&#26412;&#12290;
&#25105;&#20497;&#24456;&#39640;&#33288;&#26377;&#26032;&#33290;&#25237;&#36039;&#32773;&#30340;&#21152;&#20837;&#65292;&#35731;&#25105;&#20497;&#30906;&#20445;&#26377;&#36275;&#22816;&#30340;&#36039;&#28304;&#20358;&#32380;&#32396;&#22519;&#34892;&#25105;&#20497;&#30340;&#26989;&#21209;&#35336;&#21123;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#27492;&#22806;&#65292;&#32654;&#22283;&#35657;&#21048;&#20132;&#26131;&#22996;&#21729;&#26371;&#24050;&#26044;2020&#24180;12&#26376;28&#26085;&#25209;&#20934;&#20102;S-1&#35387;&#20874;&#25991;&#20214;&#65292;&#23559;&#37096;&#20998;&#32929;&#26481;&#25152;&#25793;&#26377;&#36229;&#36942;400&#33836;&#32929;&#32929;&#31080;&#26377;&#25928;&#22320;&#35387;&#20874;&#30332;&#34892;&#12290;
&#36889;&#23559;&#21487;&#20197;&#22686;&#21152;&#25105;&#20497;&#22312;&#22806;&#27969;&#36890;&#30340;&#32929;&#31080;&#25976;&#37327;&#20197;&#21450;&#21050;&#28608;&#32929;&#31080;&#20132;&#26131;&#30340;&#27969;&#21205;&#24615;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo --><B>3</B><!-- Field: /Sequence --> of <B>7</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B><U>2021 &ndash; The Year Ahead&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">During the first quarter of 2021, we anticipate receiving
approval from the Australia Therapeutic Goods Administration (TGA) to proceed with the pivotal clinical trial for Vitargus&reg;.
Since one or more of the potential pharmaceutical partners for the distribution of this medical device will be funding the pivotal
trial, receipt of this approval will be a key milestone leading to a distribution and manufacturing agreement. Any such agreement
will bring the first significant revenue generated from our pipeline of drugs and medical devices.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Also, during the first half of 2021, we hope to execute
a licensing agreement with a Chinese pharmaceutical company for China distribution of our Corneal Storage Solution, ABV-2002. This
agreement, if finalized, will require the Chinese partner to (a) obtain China FDA approval for marketing in China, at their expense
and (b) pay milestone payments to ABVC beginning in the first or second quarter of 2021. Further, we intend to submit a Premarket
Notification 510(K) submission to the United States and Taiwan FDAs before the end of 2021 to demonstrate that ABV-2002 is at least
as safe and effective as current products on the market.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>2021 -&#26410;&#20358;&#30340;&#19968;&#24180;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#22312;2021&#24180;&#31532;&#19968;&#23395;&#24230;&#65292;&#25105;&#20497;&#38928;&#35336;&#23559;&#29554;&#24471;&#28595;&#27954;&#25919;&#24220;&#34277;&#29289;&#31649;&#29702;&#23616;&#65288;TGA&#65289;&#30340;&#25209;&#20934;&#65292;&#23637;&#38283;Vitargus&reg;&#30340;&#38364;&#37749;&#33256;&#24202;&#35430;&#39511;&#12290;&#30001;&#26044;&#23559;&#26377;&#19968;&#20491;&#25110;&#22810;&#20491;&#28507;&#22312;&#30340;&#21512;&#20316;&#22821;&#20276;&#31561;&#33879;&#21152;&#20837;Vitargus&reg;&#30340;&#21830;&#26989;&#21270;&#38283;&#30332;&#25110;&#25552;&#20379;&#33256;&#24202;&#35430;&#39511;&#38656;&#35201;&#30340;&#36039;&#37329;&#65292;&#22240;&#27492;&#65292;&#29554;&#24471;&#25919;&#24220;&#25209;&#20934;&#23559;&#26159;&#36948;&#25104;&#20998;&#37559;&#20195;&#29702;&#21644;&#35069;&#36896;&#21332;&#35696;&#30340;&#38364;&#37749;&#37324;&#31243;&#30865;&#12290;&#36948;&#25104;&#20219;&#20309;&#21512;&#20316;&#21332;&#35696;&#37117;&#23559;&#28858;&#25105;&#20497;&#20844;&#21496;&#24118;&#20358;&#31532;&#19968;&#31558;&#21487;&#35264;&#25910;&#20837;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#27492;&#22806;&#65292;&#25105;&#20497;&#24076;&#26395;&#22312;2021&#24180;&#19978;&#21322;&#24180;&#33287;&#19968;&#23478;&#20013;&#22283;&#35069;&#34277;&#20844;&#21496;&#31805;&#32626;&#25480;&#27402;&#21332;&#35696;&#65292;&#35731;&#20182;&#20497;&#21487;&#20197;&#22312;&#20013;&#22283;&#37559;&#21806;&#25105;&#20497;&#30340;&#35282;&#33180;&#20445;&#23384;&#28082;-
ABV-2002&#12290;&#35442;&#21332;&#35696;&#20839;&#23481;&#23559;&#21253;&#21547;&#65288;a&#65289;&#34987;&#25480;&#27402;&#26041;&#33258;&#36027;&#29554;&#24471;&#20013;&#22283;FDA&#30340;&#25209;&#20934;&#65292;&#22312;&#20013;&#22283;&#36914;&#34892;&#35069;&#36896;&#33287;&#37559;&#21806;&#65292;&#20197;&#21450;&#65288;b&#65289;&#24478;2021&#24180;&#31532;&#19968;&#23395;&#24230;&#25110;&#31532;&#20108;&#23395;&#24230;&#38283;&#22987;&#21521;ABVC&#25903;&#20184;&#37324;&#31243;&#30865;&#36948;&#25104;&#37329;&#12290;&#27492;&#22806;&#65292;&#25105;&#20497;&#25171;&#31639;&#22312;2021&#24180;&#24213;&#20043;&#21069;&#21521;&#32654;&#22283;&#21644;&#21488;&#28771;FDA&#25552;&#20132;510&#65288;K&#65289;-&#19978;&#24066;&#21069;&#36890;&#21578;&#65292;&#34920;&#26126;ABV-2002&#33287;&#24066;&#22580;&#19978;&#30340;&#29694;&#26377;&#29986;&#21697;&#19968;&#27171;&#23433;&#20840;&#21644;&#26377;&#25928;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo --><B>4</B><!-- Field: /Sequence --> of <B>7</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>ABV-1504, 1505 and 1601</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">In the first quarter of 2021, we
will initiate an ABV-1601 Phase II Part 1 clinical trial for the treatment of major depression disorder in cancer patients at Cedars-Sinai
Medical Center in Los Angeles, California. The clinical study report (CSR) should be finalized at the year end. In the second quarter
of 2021, we plan to initiate a Phase II, Part 2 clinical trial of ABV-1505 for ADHD. The CSRs of ABV-1504 Phase II for MDD, ABV-1601
Phase II for MDD for cancer patients and ABV-1505 Phase II for ADHD will enable us to have further discussions with major pharmaceutical
companies about funding Phase III clinical trials and distribution. We believe that ABV-1504, ABV-1505 and ABV-1601 have the potential
to be significant new entries in the market to alleviate depression and attention deficit hyperactivity disorders since they both
offer alternative treatments with more promising outcomes and fewer serious adverse side effects than the current standard of care.
Traditional antidepressants, such as SSRI's, MAO inhibitors and TCA's have been used in the treatment of depression over the last
few decades, although none are ubiquitous in efficacy, and each have their own share of adverse side effects. SSRI's for example
can result in anxiety, sleep disruption and weight gain alongside gastrointestinal events. Our active ingredient PDC-1421, in comparison,
has less adverse side effects.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>ABV-1504, 1505 &#21644; 1601</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#21516;&#27171;&#26044;2021&#24180;&#31532;&#19968;&#23395;&#24230;&#65292;&#25105;&#20497;&#23559;&#22312;&#21152;&#24030;&#27931;&#26441;&#30959;&#24066;&#30340;Cedars-Sinai&#37291;&#23416;&#20013;&#24515;&#21855;&#21205;ABV-1601
&#33256;&#24202;II&#26399;&#31532;1&#37096;&#20998;&#35430;&#39511;&#65292;&#29992;&#26044;&#27835;&#30274;&#30284;&#30151;&#30149;&#24739;&#30340;&#24962;&#39729;&#30151;&#65292;&#32780;&#33256;&#24202;&#30740;&#31350;&#22577;&#21578;&#65288;CSR&#65289;&#25033;&#35442;&#26371;&#22312;&#24180;&#24213;&#23436;&#25104;&#12290;&#25509;&#33879;&#65292;&#31532;&#20108;&#23395;&#26371;&#21855;&#21205;ABV-1505
ADHD&#30340;&#33256;&#24202;II&#26399;&#31532;2&#37096;&#20998;&#35430;&#39511;&#12290; &#26377;&#33879;ABV-1504 (&#37325;&#24230;&#25233;&#39729;&#30151;)&#12289;
ABV-1505 (&#27880;&#24847;&#21147;&#19981;&#38598;&#20013;&#21450;&#36942;&#21205;&#30151;) &#20197;&#21450; ABV-1601(&#30284;&#30151;&#30149;&#24739;&#30340;&#24962;&#39729;&#30151;)&#23436;&#25972;&#30340;&#33256;&#24202;II&#26399;&#35430;&#39511;&#22577;&#21578;&#65292;&#25105;&#20497;&#20415;&#33021;&#22816;&#33287;&#22823;&#22411;&#35069;&#34277;&#20844;&#21496;&#36914;&#19968;&#27493;&#35342;&#35542;&#21512;&#20316;&#20006;&#36039;&#21161;&#33256;&#24202;III&#26399;&#35430;&#39511;&#20043;&#22519;&#34892;&#12290;&#25105;&#20497;&#35469;&#28858;&#65292;ABV-1504&#12289;
ABV-1505 &#20197;&#21450; ABV-1601&#30342;&#21313;&#20998;&#20855;&#26377;&#24066;&#22580;&#28507;&#21147;&#65292;&#22240;&#28858;&#23427;&#20497;&#27604;&#36215;&#29694;&#34892;&#24962;&#39729;&#30151;&#34277;&#29289;&#26377;&#33879;&#26356;&#22909;&#30340;&#32080;&#26524;&#19988;&#26356;&#23569;&#30340;&#21103;&#20316;&#29992;&#12290;&#22312;&#36942;&#21435;&#30340;&#24190;&#21313;&#24180;&#20013;&#65292;&#20659;&#32113;&#30340;&#25239;&#24962;&#39729;&#34277;&#65292;&#20363;&#22914;SSRI's&#65292;MAO&#25233;&#35069;&#21137;&#21644;TCA's&#24050;&#34987;&#29992;&#26044;&#27835;&#30274;&#24962;&#39729;&#30151;&#65292;&#20760;&#31649;&#36889;&#24190;&#27454;&#34277;&#29289;&#30342;&#20855;&#26377;&#30274;&#25928;&#65292;&#20294;&#21508;&#33258;&#37117;&#26371;&#29986;&#29983;&#19981;&#33391;&#21103;&#20316;&#29992;&#12290;&#20363;&#22914;&#65292;SSRI&#26371;&#23566;&#33268;&#28966;&#24942;&#65292;&#30561;&#30496;&#20013;&#26039;&#21644;&#39636;&#37325;&#22686;&#21152;&#20197;&#21450;&#32963;&#33144;&#36947;&#19981;&#36969;&#12290;&#30456;&#27604;&#20043;&#19979;&#65292;&#25105;&#20497;&#30340;&#27963;&#24615;&#25104;&#20998;PDC-1421&#36611;&#23569;&#29986;&#29983;&#19981;&#33391;&#30340;&#21103;&#20316;&#29992;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Based upon our discussions with potential partners for the
manufacture and distribution of ABV-1504, ABV-1505 and ABV-1601, we believe it is important to demonstrate a secure and consistent
source of the plant material, <I>Polygala tenuifolia</I>, from which the active ingredient for these medicines is derived. As a
result, much of our focus in 2021 will be directed toward establishing a supply chain for this plant material (and other medicinal
plants) from both China and a western country, such as Canada.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#26681;&#25818;&#25105;&#20497;&#33287;&#28507;&#22312;&#21512;&#20316;&#22821;&#20276;&#37341;&#23565;ABV-1504&#65292;ABV-1505&#21644;ABV-1601&#30340;&#35342;&#35542;&#65292;&#25105;&#20497;&#35469;&#28858;&#37325;&#35201;&#30340;&#19968;&#20214;&#20107;&#26159;&#25105;&#20497;&#33021;&#22816;&#30906;&#20445;&#21547;&#26377;&#27835;&#30274;&#30142;&#30149;&#26377;&#25928;&#25104;&#20998;&#30340;&#36960;&#24535;&#26893;&#29289;&#20854;&#29986;&#22320;&#20358;&#28304;&#30340;&#19968;&#33268;&#24615;&#12290;
&#22240;&#27492;&#65292;&#25105;&#20497;&#22312;2021&#24180;&#30340;&#19968;&#22823;&#37325;&#40670;&#23601;&#22312;&#26044;&#24314;&#31435;&#36960;&#24535;&#26893;&#29289;
(&#21644;&#20854;&#20182;&#34277;&#29992;&#26893;&#29289;)&#30340;&#20379;&#25033;&#37832;&#65292;&#28961;&#35542;&#26159;&#24478;&#20013;&#22283;&#25110;&#35199;&#26041;&#22283;&#23478;&#65292;&#27604;&#22914;&#35498;&#21152;&#25343;&#22823;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo --><B>5</B><!-- Field: /Sequence --> of <B>7</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>ABV-1703</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">In the second half of 2021, we will start an ABV-1703 Phase
II Part 1clinical trial of Maitake BLEX404 oral liquid drug for the treatment of metastatic pancreatic cancer and biliary tract
cancer at Cedars-Sinai Medical Center in Los Angeles, California. If Part 1 is successful, the second part of Phase II will be
conducted as a multi-nation, multi-site study including at least one major medical center in Taiwan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#22312;2021&#24180;&#19979;&#21322;&#24180;&#65292;&#25105;&#20497;&#23559;&#22312;&#21152;&#24030;&#27931;&#26441;&#30959;&#24066;&#30340;Cedars-Sinai&#37291;&#23416;&#20013;&#24515;&#21855;&#21205;ABV-1703&#33256;&#24202;II&#26399;&#31532;1&#37096;&#20998;&#35430;&#39511;&#65292;&#36889;&#26159;&#20351;&#29992;&#33310;&#33592;
BLEX404&#20570;&#25104;&#30340;&#21475;&#26381;&#28082;&#39636;&#34277;&#29289;&#29992;&#26044;&#27835;&#30274;&#33008;&#33247;&#30284;&#21644;&#33213;&#31649;&#30284;&#12290;&#22914;&#26524;ABV-1703&#33256;&#24202;
II&#26399;&#31532;1&#37096;&#20998;&#29554;&#24471;&#25104;&#21151;&#65292;&#21063;&#33256;&#24202;II&#26399;&#31532;2&#37096;&#20998;&#23559;&#36914;&#19968;&#27493;&#20316;&#25104;&#22810;&#22283;&#65292;&#22810;&#22320;&#40670;&#30340;&#33256;&#24202;&#35430;&#39511;&#65292;&#20854;&#20013;&#33267;&#23569;&#26371;&#21253;&#25324;&#19968;&#38291;&#21488;&#28771;&#20027;&#35201;&#30340;&#37291;&#23416;&#20013;&#24515;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>BioKey</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">In 2019, we completed our acquisition of BioKey, Inc., located
in Fremont, California. BioKey is a valuable addition to ABVC that provides Contract Development &amp; Manufacturing Organization&nbsp;services
to discovery biotechnology companies engaged in clinical trials of various drugs. Its GMP manufacturing facility can produce short
runs of capsules, tablets or solutions needed for clinical trials. In 2020, BioKey suffered revenue losses of approximately $500,000,
so our main goal for 2021 is to bring the business to profitability. To reach that goal, we appointed Dr. Richard King as BioKey&rsquo;s
CEO to lead the turnaround of this subsidiary; he will continue to engage in his role as the Chief Science Officer of ABVC.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><B>BioKey &#20844;&#21496;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#22312;2019&#24180;&#65292;&#25105;&#20497;&#23436;&#25104;&#20102;&#19968;&#23478;&#37291;&#34277;&#20844;&#21496;
- BioKey&#30340;&#25910;&#36092;&#65292;&#20844;&#21496;&#20301;&#26044;&#21152;&#24030;Fremont &#24066;&#12290;&#25910;&#36092;&#24460;&#25104;&#28858;ABVC&#37325;&#35201;&#30340;&#20379;&#25033;&#37832;&#65292;BioKey&#24288;&#20839;&#21487;&#24478;&#20107;&#21508;&#31278;&#33256;&#24202;&#35430;&#39511;&#34277;&#29289;&#30340;&#29983;&#29289;&#25216;&#34899;&#38283;&#30332;&#65292;&#20006;&#25552;&#20379;&#21512;&#32004;&#38283;&#30332;&#21450;&#35069;&#36896;&#26381;&#21209;&#12290;
&#23427;&#30340;GMP&#29983;&#29986;&#35373;&#26045;&#21487;&#20197;&#29983;&#29986;&#30701;&#26399;&#20351;&#29992;&#30340;&#33184;&#22218;&#65292;&#29255;&#21137;&#25110;&#20379;&#33256;&#24202;&#35430;&#39511;&#25152;&#38656;&#30340;&#28342;&#28082;&#12290;
2020&#24180;&#65292;BioKey&#38754;&#33256;&#20102;&#22823;&#32004;500,000&#32654;&#20803;&#30340;&#34407;&#25613;&#65292;&#22240;&#27492;&#25105;&#20497;2021&#24180;&#30340;&#20027;&#35201;&#30446;&#27161;&#26159;&#20351;&#35442;&#20844;&#21496;&#26989;&#21209;&#22686;&#38263;&#33267;&#23526;&#29694;&#30408;&#21033;&#12290;
&#28858;&#20102;&#23526;&#29694;&#36889;&#19968;&#30446;&#27161;&#65292;&#25105;&#20497;&#20219;&#21629;&#20102;Richard King&#21338;&#22763;&#28858;BioKey&#30340;&#22519;&#34892;&#38263;&#65292;&#24118;&#38936;BioKey&#25197;&#34407;&#28858;&#30408;&#65292;&#26044;&#27492;&#21516;&#26178;&#20182;&#23559;&#32380;&#32396;&#25812;&#20219;ABVC&#30340;&#30740;&#30332;&#38263;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2021 will be a busy year for the company with one of our main
goals being to strengthen our management team to better support clinical trials ongoing throughout the year and add new medicines
to our pipeline. Further, we are considering additional financing later in the year to accelerate our growth and will need to expand
our financial and administrative teams to help manage that growth.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#23637;&#26395;2021&#24180;&#65292;&#26377;&#35377;&#22810;&#37325;&#35201;&#30340;&#30446;&#27161;&#31561;&#33879;ABVC&#22296;&#38538;&#21435;&#36948;&#25104;&#12290;&#20854;&#20013;&#20027;&#35201;&#30446;&#27161;&#20043;&#19968;&#26159;&#21152;&#24375;&#22296;&#38538;&#30340;&#31649;&#29702;&#65292;&#26356;&#26377;&#25928;&#29575;&#22320;&#25903;&#25345;&#27491;&#22312;&#36914;&#34892;&#30340;&#33256;&#24202;&#35430;&#39511;&#65292;&#21516;&#26178;&#22686;&#21152;&#26032;&#34277;&#30340;&#38283;&#30332;&#65292;&#28858;&#25105;&#20497;&#30340;&#29986;&#21697;&#32218;&#28155;&#21152;&#26032;&#33394;&#24425;&#12290;
&#36996;&#26377;&#65292;&#25105;&#20497;&#20063;&#32771;&#24942;&#26044;&#20170;&#24180;&#30340;&#19979;&#21322;&#24180;&#36879;&#36942;&#22686;&#21152;&#34701;&#36039;&#21152;&#36895;&#25512;&#21205;&#33256;&#24202;&#35430;&#39511;&#65292;&#25844;&#22823;&#25105;&#20497;&#30340;&#36001;&#21209;&#21644;&#34892;&#25919;&#22296;&#38538;&#20358;&#37197;&#21512;&#20844;&#21496;&#30340;&#25104;&#38263;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo --><B>6</B><!-- Field: /Sequence --> of <B>7</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When Dr. Jiang founded ABVC, his vision was to create a company
that would serve as a conduit to introduce Asia-Pacific medicines to the rest of the world. That vision is starting to become a
reality now that the West is beginning to accept botanical medicines from the Asia-Pacific region as a means of addressing stubborn
illnesses. We believe the company&rsquo;s plant derived medicines can bring greater safety and improved efficacy than the drugs
currently available to western patients. For all of this, he and I would like to thank our shareholders for your confidence, patience
and support.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#27743;&#21338;&#22763;&#21109;&#31435;ABVC&#26178;&#65292;&#20182;&#30340;&#39000;&#26223;&#26159;&#21109;&#24314;&#19968;&#23478;&#20844;&#21496;&#33021;&#22816;&#20316;&#28858;&#21521;&#19990;&#30028;&#20854;&#20182;&#22320;&#21312;&#20171;&#32057;&#20126;&#22826;&#22320;&#21312;&#29305;&#26377;&#34277;&#21697;&#30340;&#28192;&#36947;&#12290;
&#29694;&#22312;&#65292;&#35199;&#26041;&#22283;&#23478;&#28472;&#28472;&#38283;&#22987;&#25509;&#21463;&#20358;&#33258;&#20126;&#22826;&#22320;&#21312;&#30340;&#26893;&#29289;&#34277;&#20316;&#28858;&#25033;&#23565;&#38929;&#22266;&#30142;&#30149;&#30340;&#25163;&#27573;&#65292;&#20182;&#30340;&#36889;&#19968;&#39000;&#26223;&#24050;&#36880;&#27493;&#23526;&#29694;&#12290;
&#25105;&#20497;&#35469;&#28858;ABVC&#24478;&#26893;&#29289;&#34893;&#29983;&#30340;&#34277;&#29289;&#27604;&#36215;&#35199;&#26041;&#22283;&#23478;&#24066;&#22580;&#19978;&#29694;&#26377;&#34277;&#29289;&#20855;&#26377;&#26356;&#39640;&#30340;&#23433;&#20840;&#24615;&#21644;&#30274;&#25928;&#12290;&#20063;&#22240;&#28858;&#22533;&#25345;&#36889;&#20491;&#29702;&#24565;&#65292;&#25105;&#21644;&#20182;&#35201;&#24863;&#35613;&#25105;&#20497;&#25152;&#26377;&#30340;&#32929;&#26481;&#23565;&#25105;&#20497;&#30340;&#20449;&#20219;&#12289;&#32784;&#24515;&#21644;&#25903;&#25345;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 5, 2021</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Howard Doong,</FONT> M.D., Ph.
D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">American BriVision (Holding) Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page <B>7</B> of
<B>7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-right: 0; margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="margin-right: 0; font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea132646ex99-2_american.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>American
BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FREMONT,
CA (January 6, 2021) &ndash; American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company
developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, yesterday issued a letter
to its more than 700 shareholders describing the company&rsquo;s achievements in 2020 and goals for 2021. The letter from Dr.
Howard Doong, CEO of ABVC, is reprinted below in its entirety.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Shareholder:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Now
that 2020 has ended, we believe it will be informative to you, our shareholders, to hear about our goals for 2021. But first,
we note that 2020 was an exceptional year for the company, particularly with respect to our medical device, Vitargus&reg;, and
our medicine ABV-1505, which is designed to alleviate attention-deficit hyperactivity disorder (ADHD).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020
- A Year of Accomplishment</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: 0.3in; margin-top: 0; margin-bottom: 0; width: 95%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vitargus&reg;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vitargus&reg;
is the world&rsquo;s first bio-degradable vitreous substitute utilized during vitrectomy surgery. Vitargus&reg; offers important
advantages over current vitreous substitutes by minimizing medical complications and reducing the need for additional surgeries.
In October of 2020, we sent a full clinical study report (CSR) of Vitargus&reg; First-in-Human Phase I Clinical Trial to the United
States Food and Drug Administration. The participants in the study showed significant improvement in visual acuity immediately
following retina re-attachment surgery. Additionally, since Vitargus&reg; is a stable semisolid gel adhering to the retina during
surgery, patients do not need to remain face-down after surgery, which provides a significant improvement to patients&rsquo; post-surgical
comfort. Vitargus&reg; addresses a large and growing market according to Grand View Research, with worldwide vitrectomy cases
expected to increase from 1.26 million in 2012 to 4 million by 2030 (6.8% CAGR), reaching a $2 billion market value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABV-1505
- ADHD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Equally as exciting, a successful
Phase II, Part 1 Clinical Trial of ABV 1505 was completed at the University of California, San Francisco (UCSF) Medical Center
and a clinical study report (CSR) was issued this past November. ABV-1505 targets adult attention deficit disorder and has the
same active pharmaceutical ingredient, PDC-1421, used in ABV-1504, one of our drugs that successfully completed a Phase II clinical
study conducted at Stanford University to treat major depression disorder (MDD) in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">In July of 2020, we filed for a patent
for certain aspects of ABV-1504 in the United States under the <FONT STYLE="background-color: #FAFAFA">Patent Cooperation Treaty
(PCT); this treaty has legal effect in other countries. We believe that the patent, when granted, will greatly enh</FONT>ance our
existing portfolio of PDC-1421 related patents and strengthen our global IP position. PDC-1421, the active ingredient in ABV-1504
and ABV-1505, is an extract of <I>Polygala tenuifolia,</I> a plant grown primarily in China.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABV-2002
&ndash; Corneal Storage Solution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
November 4, 2020, we executed an amendment to our development collaboration agreement with BioFirst, an affiliate, to add a Corneal
Storage Solution and an Intraocular Irrigation Solution to the agreement. The Corneal Storage Solution is utilized during a corneal
transplant procedure to replace a damaged or diseased cornea. The Intraocular Irrigation Solution has broader utilization and
is used during a variety of ocular procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initially,
ABVC will focus on the Corneal Storage Solution, designated ABV-2002 under ABVC&rsquo;s product identification system. A donor
cornea is stored in the ABV-2002 solution prior to penetrating keratoplasty (full thickness cornea transplant) or endothelial
keratoplasty (back layer cornea transplant). Early testing indicates that ABV-2002 may be more effective at protecting the cornea
during long-term storage than other storage media currently available and can be manufactured at lower cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
2020 was a year that set the stage for a potential listing on NASDAQ, an elusive goal we have been pursuing for over a year. To
reach this goal and fund our clinical trials, we improved our balance sheet during the year by raising more than $8.0 million
of fresh equity and converting more than $4.0 million of debt to equity. We are pleased that both new and previous investors stepped
up to assure that we have the resources to continue the execution of our business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, on December 28, 2020 an S-1 registration statement to register more than 4 million shares already owned by our shareholders
was declared effective by the US Securities &amp; Exchange Commission. This will increase the number of shares in our outstanding
share float which we believe will result in an increase in the liquidity of our stock trading.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021
&ndash; The Year Ahead</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: 0.3in; margin-top: 0; margin-bottom: 0; width: 95%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the first quarter of 2021, we anticipate receiving approval from the Australia Therapeutic Goods Administration (TGA) to proceed
with the pivotal clinical trial for Vitargus&reg;. Since one or more of the potential pharmaceutical partners for the distribution
of this medical device will be funding the pivotal trial, receipt of this approval will be a key milestone leading to a distribution
and manufacturing agreement. Any such agreement will bring the first significant revenue generated from our pipeline of drugs
and medical devices.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
during the first half of 2021, we hope to execute a licensing agreement with a Chinese pharmaceutical company for China distribution
of our Corneal Storage Solution, ABV-2002. This agreement, if finalized, will require the Chinese partner to (a) obtain China
FDA approval for marketing in China, at their expense and (b) pay milestone payments to ABVC beginning in the first or second
quarter of 2021. Further, we intend to submit a Premarket Notification 510(K) submission to the United States and Taiwan FDAs
before the end of 2021 to demonstrate that ABV-2002 is at least as safe and effective as current products on the market.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0in 0pt 0.3in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABV-1504,
1505 and 1601</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of 2021, we will initiate an ABV-1601 Phase II Part 1 clinical trial for the treatment of major depression
disorder in cancer patients at Cedars-Sinai Medical Center in Los Angeles, California. The clinical study report (CSR) should
be finalized at the year end. In the second quarter of 2021, we plan to initiate a Phase II, Part 2 clinical trial of
ABV-1505 for ADHD. The CSRs of ABV-1504 Phase II for MDD, ABV-1601 Phase II for MDD for cancer patients and ABV-1505 Phase II
for ADHD will enable us to have further discussions with major pharmaceutical companies about funding Phase III clinical
trials and distribution. We believe that ABV-1504, ABV-1505 and ABV-1601 have the potential to be significant new entries in
the market to alleviate depression and attention deficit hyperactivity disorders since they both offer alternative treatments
with more promising outcomes and fewer serious adverse side effects than the current standard of care. Traditional
antidepressants, such as SSRI&rsquo;s, MAO inhibitors and TCA&rsquo;s have been used in the treatment of depression over the
last few decades, although none are ubiquitous in efficacy, and each have their own share of adverse side effects.
SSRI&rsquo;s for example can result in anxiety, sleep disruption and weight gain alongside gastrointestinal events. Our
active ingredient PDC-1421, in comparison, has less adverse side effects.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Based upon our discussions with potential
partners for the manufacture and distribution of ABV-1504, ABV-1505 and ABV-1601, we believe it is important to demonstrate a secure
and consistent source of the plant material, <I>Polygala tenuifolia</I>, from which the active ingredient for these medicines is
derived. As a result, much of our focus in 2021 will be directed toward establishing a supply chain for this plant material (and
other medicinal plants) from both China and a western country, such as Canada.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABV-1703</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the second half of 2021, we will start an ABV-1703 Phase II Part 1 clinical trial of Maitake BLEX404 oral liquid drug for the
treatment of metastatic pancreatic cancer and biliary tract cancer at Cedars-Sinai Medical Center in Los Angeles, California.
If Part 1 is successful, the second part of Phase II will be conducted as a multi-nation, multi-site study including at least
one major medical center in Taiwan.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BioKey</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2019, we completed our acquisition of BioKey, Inc., located in Fremont, California. BioKey is a valuable addition to ABVC that
provides Contract Development &amp; Manufacturing Organization&nbsp;services to discovery biotechnology companies engaged in clinical
trials of various drugs. Its GMP manufacturing facility can produce short runs of capsules, tablets or solutions needed for clinical
trials. In 2020, BioKey suffered revenue losses of approximately $500,000, so our main goal for 2021 is to bring the business
to profitability. To reach that goal, we appointed Dr. Richard King as BioKey&rsquo;s CEO to lead the turnaround of this subsidiary;
he will continue to engage in his role as the Chief Science Officer of ABVC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0in 0pt 0.3in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021 will be a busy year for the company with one of
our main goals being to strengthen our management team to better support clinical trials ongoing throughout the year and add new
medicines to our pipeline. Further, we are considering additional financing later in the year to accelerate our growth and will
need to expand our financial and administrative teams to help manage that growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
Dr. Jiang founded ABVC, his vision was to create a company that would serve as a conduit to introduce Asia-Pacific medicines to
the rest of the world. That vision is starting to become a reality now that the West is beginning to accept botanical medicines
from the Asia-Pacific region as a means of addressing stubborn illnesses. We believe the company&rsquo;s plant derived medicines
can bring greater safety and improved efficacy than the drugs currently available to western patients. For all of this, he and
I would like to thank our shareholders for your confidence, patience and support.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0in 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">January 5, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Howard Doong, M.D., Ph. D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">American BriVision (Holding) Corporation</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are in early stages, and there is no guarantee that any specific outcome will be achieved. This press release contains
&ldquo;forward-looking statements.&rdquo; Such statements may be preceded by the words &ldquo;intends,&rdquo; &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;plans,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;aims,&rdquo; &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;potential,&rdquo; or similar
words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject
to various known and unknown risks and uncertainties, many of which are beyond the Company&rsquo;s control, and cannot be predicted
or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability
to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties
in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of
one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of
the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that
may affect the realization of forward-looking statements is set forth in the Company&rsquo;s filings with the Securities and Exchange
Commission (SEC), including the Company&rsquo;s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are
urged to read these documents free of charge on the SEC&rsquo;s website at&nbsp;<B>http://www.sec.gov</B>. The Company assumes
no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">This press release does not constitute an offer to sell
or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such
state or jurisdiction.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andy
An &ndash; Chief Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">765-610-8826</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">andyan@ambrivis.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">4</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  N (4# 2(  A$! Q$!_\0
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M66>&,RLN^5%RP_6:"""U@AM;:)(+:VABM[>&-=L<,$*+%#$BCA4CC544#@
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M=?V\MI>V-Y#'<6EW:SH8YK>X@E5HY8I$8JZ.I4@]*_/GXG_L-VTD]YK7PO\
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M/I\]Q/ 64X.U[FSLY"/<Q ^U>K?"[]G;QE\5GSH^K^&=+M4^:6?4KC59+A$
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C+A88Y8?#I4J*PN!5+#JG!62HPE7HRC#>W-2@Y:R:;DY2_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
